OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by increased cardiovascular risk in adult-onset and childhood-onset SLE. Type I interferons (IFNs) appear to play a prominent role in premature vascular damage in adult-onset SLE, at least in part, by inducing impairments in the phenotype and function of endothelial progenitor cells (EPCs), thereby hampering vascular repair. It is not clear whether EPC dysfunction is present in childhood-onset SLE in association with a type I IFN signature. METHODS: The phenotype and numbers of EPCs were quantified in patients with childhood-onset SLE, patients with juvenile idiopathic arthritis (JIA), and matched healthy control subjects. In a separate cohort of patients with childhood-onset SLE, markers of subclinical atherosclerosis and endothelial dysfunction were quantified using standardized protocols and analyzed for associations with serum type I IFN activity. RESULTS: EPC numbers and function were significantly decreased in patients with childhood-onset SLE compared with patients with JIA and healthy control subjects. Serum from patients with childhood-onset SLE impaired differentiation of EPCs into mature endothelial cells in healthy controls, and this effect was blocked by inhibition of the type I IFN pathway. Type I IFN activity in serum was not significantly associated with subclinical atherosclerosis and endothelial function in patients with childhood-onset SLE. CONCLUSION: As in adult-onset SLE, childhood-onset SLE is characterized by phenotypic and functional EPC abnormalities, which are likely triggered by type I IFNs. Although cross-sectional analysis revealed no global association between type I IFN signatures and vascular measures of subclinical atherosclerosis, longitudinal assessments are needed to evaluate whether progression of vascular damage in patients with childhood-onset SLE is associated with type I IFNs, as observed in patients with adult-onset SLE.
OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by increased cardiovascular risk in adult-onset and childhood-onset SLE. Type I interferons (IFNs) appear to play a prominent role in premature vascular damage in adult-onset SLE, at least in part, by inducing impairments in the phenotype and function of endothelial progenitor cells (EPCs), thereby hampering vascular repair. It is not clear whether EPC dysfunction is present in childhood-onset SLE in association with a type I IFN signature. METHODS: The phenotype and numbers of EPCs were quantified in patients with childhood-onset SLE, patients with juvenile idiopathic arthritis (JIA), and matched healthy control subjects. In a separate cohort of patients with childhood-onset SLE, markers of subclinical atherosclerosis and endothelial dysfunction were quantified using standardized protocols and analyzed for associations with serum type I IFN activity. RESULTS: EPC numbers and function were significantly decreased in patients with childhood-onset SLE compared with patients with JIA and healthy control subjects. Serum from patients with childhood-onset SLE impaired differentiation of EPCs into mature endothelial cells in healthy controls, and this effect was blocked by inhibition of the type I IFN pathway. Type I IFN activity in serum was not significantly associated with subclinical atherosclerosis and endothelial function in patients with childhood-onset SLE. CONCLUSION: As in adult-onset SLE, childhood-onset SLE is characterized by phenotypic and functional EPC abnormalities, which are likely triggered by type I IFNs. Although cross-sectional analysis revealed no global association between type I IFN signatures and vascular measures of subclinical atherosclerosis, longitudinal assessments are needed to evaluate whether progression of vascular damage in patients with childhood-onset SLE is associated with type I IFNs, as observed in patients with adult-onset SLE.
Authors: J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal Journal: Arthritis Rheum Date: 2001-10
Authors: Nikos Werner; Sonja Kosiol; Tobias Schiegl; Patrick Ahlers; Katrin Walenta; Andreas Link; Michael Böhm; Georg Nickenig Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245
Authors: Sanjay Rajagopalan; Emily C Somers; Robert D Brook; Christine Kehrer; Dana Pfenninger; Emily Lewis; Anjan Chakrabarti; Bruce C Richardson; Eric Shelden; W Joseph McCune; Mariana J Kaplan Journal: Blood Date: 2004-01-15 Impact factor: 22.113
Authors: Elaine M Urbina; Richard V Williams; Bruce S Alpert; Ronnie T Collins; Stephen R Daniels; Laura Hayman; Marc Jacobson; Larry Mahoney; Michele Mietus-Snyder; Albert Rocchini; Julia Steinberger; Brian McCrindle Journal: Hypertension Date: 2009-09-03 Impact factor: 10.190
Authors: Emily C Somers; Wenpu Zhao; Emily E Lewis; Lu Wang; Jeffrey J Wing; Baskaran Sundaram; Ella A Kazerooni; W Joseph McCune; Mariana J Kaplan Journal: PLoS One Date: 2012-05-14 Impact factor: 3.240
Authors: Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight Journal: Ann Rheum Dis Date: 2016-07-18 Impact factor: 19.103
Authors: Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider Journal: J Rheumatol Date: 2019-08-01 Impact factor: 4.666
Authors: Mariana J Kaplan; Massimo Gadina; Yasuko Furumoto; Carolyne K Smith; Luz Blanco; Wenpu Zhao; Stephen R Brooks; Seth G Thacker; Zarzour Abdalrahman; Giuseppe Sciumè; Wanxia L Tsai; Anna M Trier; Leti Nunez; Laurel Mast; Victoria Hoffmann; Alan T Remaley; John J O'Shea Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 10.995
Authors: Ashley S Manchanda; Alan C Kwan; Mariko Ishimori; Louise E J Thomson; Debiao Li; Daniel S Berman; C Noel Bairey Merz; Caroline Jefferies; Janet Wei Journal: Front Cardiovasc Med Date: 2022-04-15